
Neuralbase Appoints Tushar Shivekar as Chief Technology Officer
Bringing over 14 years of expertise in software quality engineering, automation testing, and cybersecurity, Mr. Shivekar adds deep technical leadership to the company's rapidly expanding BMP AI platform for regulated industries. His career includes pivotal roles at global technology leaders Wipro Technologies and Mindtree, where he led large-scale enterprise quality assurance initiatives for Fortune 500 clients.
At Wipro Technologies, Mr. Shivekar supported broadband infrastructure quality engineering for major telecommunications providers. During his tenure at Mindtree, he led testing initiatives for anti-phishing, cybersecurity, and enterprise compliance platforms, serving top-tier financial institutions and global e-commerce clients.
Mr. Shivekar's technical expertise spans a wide range of enterprise testing and automation tools, including Playwright, Selenium, Appium, Perfecto, Docker, REST API frameworks, as well as security testing platforms such as Burp Suite and Veracode. His combination of automation and cybersecurity knowledge directly aligns with BMP AI's mission of delivering trusted, compliant AI solutions for healthcare, financial services, legal, and enterprise clients.
Most recently, Mr. Shivekar held senior leadership roles at 7 Street Technologies and Jaaee Technologies, where he architected scalable test automation frameworks for web, mobile, and enterprise platforms, while mentoring cross-functional engineering teams and driving strategic technical initiatives.
'Tushar's rare blend of technical mastery and enterprise business acumen is exactly what the company needs as we continue scaling our BMP AI platform across regulated industries,' said Vighnesh Dabole, CEO of Neuralbase AI Ltd. 'His track record in delivering secure, high-quality, and scalable enterprise systems will be instrumental as we enter our next phase of product innovation and market expansion.'
As Chief Technology Officer, Mr. Shivekar will lead the development of the company's advanced enterprise AI infrastructure, overseeing engineering, security, and platform architecture, while driving continued innovation in our document-grounded, compliance-first AI solutions.
'Joining Neuralbase AI represents an exciting opportunity to bring together my experience in automation, quality engineering, and cybersecurity to advance trusted enterprise AI,' said Tushar Shivekar. 'Together, we will deliver AI solutions that are not only intelligent, but also secure, explainable, and aligned with the complex compliance needs of our enterprise customers.'
Additional information about the Company is available at www.neuralbase.ai or by visiting www.sec.gov.
About NEURALBASE AI
Neuralbase AI Ltd. (OTC: NBBI) is an AI company developing secure, scalable, and context-aware conversational agents and workflow automation systems. Through its BMP AI platform - now in beta testing - the company enables organizations to streamline internal operations, enhance team collaboration, and increase productivity while maintaining strict compliance and data integrity.
Legal Disclaimer and Forward-Looking Statements
This press release contains forward-looking statements as defined under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, projections, and assumptions made by Neuralbase AI Ltd. (the 'Company' or 'NBBI') in light of experience, current conditions, anticipated future developments, and other factors. Forward-looking statements may include words such as 'aims,' 'anticipates,' 'believes,' 'plans,' 'expects,' 'intends,' 'will,' 'may,' 'could,' 'should,' and similar expressions.
These statements relate to, among other things, the expected performance and capabilities of the BMP AI platform; the Company's ability to successfully complete product development, enter commercial deployment, or scale its technology; future revenues and market expansion; and general strategic direction. All such statements are inherently uncertain and involve a number of risks that could cause actual results to differ materially from those expressed or implied in any forward-looking statement.
Neuralbase AI Ltd. is a fully reporting company with the U.S. Securities and Exchange Commission (SEC) and files annual and quarterly reports, current reports, and other required disclosures. All public filings and disclosures may be reviewed at the SEC's EDGAR database at www.sec.gov. The Company trades on the OTC Markets under the ticker symbol NBBI.
This press release is not, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of Neuralbase AI Ltd. in the United States or in any other jurisdiction. Offers and sales of securities, if any, will be made only pursuant to an effective registration statement or valid exemption under the U.S. Securities Act of 1933, as amended.
Investing in securities traded on the OTC Markets involves significant risk, including potential loss of principal, low liquidity, high volatility, and limited publicly available information. Shares traded on the OTC Markets may be more susceptible to market manipulation or price swings. Investors are strongly advised to conduct their own due diligence, consult a qualified investment advisor, and carefully review all SEC filings prior to making any investment decision.
Media Contact:
Vighnesh Dobale
Chief Executive Officer
[email protected]
(727) 314-3717
View the original release on www.newmediawire.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
12 hours ago
- Business Insider
J.P. Morgan Sticks to Their Buy Rating for Suncorp Group (SNMYF)
J.P. Morgan analyst Siddharth Parameswaran maintained a Buy rating on Suncorp Group on August 14 and set a price target of A$21.20. The company's shares closed last Friday at $10.83. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Parameswaran is a 4-star analyst with an average return of 9.2% and a 66.08% success rate. Parameswaran covers the Financial sector, focusing on stocks such as ASX , AMP , and Computershare Limited. In addition to J.P. Morgan, Suncorp Group also received a Buy from Morgan Stanley's Andrei Stadnik in a report issued yesterday. However, on August 14, Citi maintained a Hold rating on Suncorp Group (Other OTC: SNMYF). Based on Suncorp Group's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.35 billion and a net profit of $1.1 billion. In comparison, last year the company earned a revenue of $9.5 billion and had a net profit of $582 million

Business Upturn
20 hours ago
- Business Upturn
LambdaTest Unveils Media Injection for Real Device Testing
Business Wire India LambdaTest, a unified agentic AI and cloud engineering platform, has launched Video Injection capability in Media Injection for real device testing, bringing powerful support for testing camera and video-based app functionalities at scale. This new capability empowers developers and QA teams to simulate image and video capture scenarios on real Android and iOS devices, unlocking comprehensive validation for camera-driven app experiences. With Media Injection, users can test key workflows like QR code and barcode scanning, digital check processing, real-time video streaming, and photo or video upload features, directly on physical devices. This is made possible through LambdaTest's proprietary Sensor Instrumentation technology, which seamlessly injects simulated media into the app's camera interface, bypassing the need for physical camera use while ensuring realistic results. Media Injection supports a wide range of commonly used camera APIs and integrates effortlessly with existing LambdaTest environments. With compatibility across more than 10,000 real devices, the feature ensures unparalleled coverage and accuracy for mission-critical camera workflows. 'Camera functionality is at the heart of many modern apps, whether it's mobile banking, streaming, or shopping,' said Jay Singh, Co-Founder at LambdaTest. 'With Media Injection, we're removing the guesswork from camera testing and giving teams the power to validate these flows with real precision and scale.' Video Injection under Media Injection is now available for all users running app tests on real devices through LambdaTest's cloud platform. For more information, please visit About LambdaTest LambdaTest is a GenAI-powered Quality Engineering Platform that empowers teams to test intelligently, smarter, and ship faster. Built for scale, it offers a full-stack testing cloud with 10K+ real devices and 3,000+ browsers. With AI-native test management, MCP servers, and agent-based automation, LambdaTest supports Selenium, Appium, Playwright, and all major frameworks. AI Agents like HyperExecute and KaneAI bring the power of AI and cloud into your software testing workflow, enabling seamless automation testing with 120+ integrations. LambdaTest Agents accelerate your testing throughout the entire SDLC, from test planning and authoring to automation, infrastructure, execution, RCA, and reporting. For more information, please visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash


Business Upturn
2 days ago
- Business Upturn
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company's innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth. Regen sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market projected to be valued at well in excess of $1 billion annually. HemaXellerate is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation. Advertisement HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells. 'Aplastic anemia patients without access to bone marrow transplantation face limited options,' said Dr. David Koos, Chairman and CEO of Regen BioPharma. 'With FDA clearance to begin clinical trials, HemaXellerate has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.' To ensure the trial's success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months. Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity. Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market. Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence. About Regen BioPharma, Inc. Regen BioPharma, Inc. is a publicly traded biotechnology company (OTC ID: RGBP) and (OTC ID: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effect of government regulation, competition and other material risks. CONTACT INFORMATION: Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-722-5505 Phone Email: [email protected] or [email protected] X (formerly twitter): Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.